DK171298B1 - Substituerede propan-1-ol-derivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdelde disse - Google Patents
Substituerede propan-1-ol-derivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdelde disse Download PDFInfo
- Publication number
- DK171298B1 DK171298B1 DK299590A DK299590A DK171298B1 DK 171298 B1 DK171298 B1 DK 171298B1 DK 299590 A DK299590 A DK 299590A DK 299590 A DK299590 A DK 299590A DK 171298 B1 DK171298 B1 DK 171298B1
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- derivatives
- alkyl
- yield
- meoh
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000001225 therapeutic effect Effects 0.000 title claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 7
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- -1 N-alkylamine Inorganic materials 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 claims 1
- 125000005210 alkyl ammonium group Chemical group 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 125000005131 dialkylammonium group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000005208 trialkylammonium group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- FNVIJAXBJSXSAU-UHFFFAOYSA-N propane;hydrobromide Chemical compound Br.CCC FNVIJAXBJSXSAU-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GVOWCTKPPKORMK-UHFFFAOYSA-N (2-phenyl-1,3-dioxan-5-yl)methanol Chemical compound O1CC(CO)COC1C1=CC=CC=C1 GVOWCTKPPKORMK-UHFFFAOYSA-N 0.000 description 1
- XJKSISNAIWKYAG-UHFFFAOYSA-N 1-bromo-5-isocyanatopentane Chemical compound BrCCCCCN=C=O XJKSISNAIWKYAG-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SBMUNILHNJLMBF-UHFFFAOYSA-N 2-chloro-1,3,2$l^{5}-dioxaphospholane 2-oxide Chemical compound ClP1(=O)OCCO1 SBMUNILHNJLMBF-UHFFFAOYSA-N 0.000 description 1
- GCNUKQDSEUZLLY-UHFFFAOYSA-N 5-(methoxymethyl)-2-phenyl-1,3-dioxane Chemical compound O1CC(COC)COC1C1=CC=CC=C1 GCNUKQDSEUZLLY-UHFFFAOYSA-N 0.000 description 1
- UFNGFGYICQRXIY-UHFFFAOYSA-N 5-bromohexanoyl chloride Chemical compound CC(Br)CCCC(Cl)=O UFNGFGYICQRXIY-UHFFFAOYSA-N 0.000 description 1
- LYIXCZTUCSFXEF-UHFFFAOYSA-N 5-ethoxycarbonyl-2-phenyl-1,3-dioxane-5-carboxylic acid Chemical compound O1CC(C(=O)OCC)(C(O)=O)COC1C1=CC=CC=C1 LYIXCZTUCSFXEF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- WIOHBOKEUIHYIC-UHFFFAOYSA-N diethyl 2,2-bis(hydroxymethyl)propanedioate Chemical compound CCOC(=O)C(CO)(CO)C(=O)OCC WIOHBOKEUIHYIC-UHFFFAOYSA-N 0.000 description 1
- YKJMZQTYPNUTLR-UHFFFAOYSA-N diethyl 2-phenyl-1,3-dioxane-5,5-dicarboxylate Chemical compound O1CC(C(=O)OCC)(C(=O)OCC)COC1C1=CC=CC=C1 YKJMZQTYPNUTLR-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- NWPJGDYRXBBGJQ-UHFFFAOYSA-N ethyl 2-phenyl-1,3-dioxane-5-carboxylate Chemical compound O1CC(C(=O)OCC)COC1C1=CC=CC=C1 NWPJGDYRXBBGJQ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical class C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/20—Quaternary compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8928580 | 1989-12-19 | ||
| GB898928580A GB8928580D0 (en) | 1989-12-19 | 1989-12-19 | 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK299590D0 DK299590D0 (da) | 1990-12-18 |
| DK299590A DK299590A (da) | 1991-06-20 |
| DK171298B1 true DK171298B1 (da) | 1996-08-26 |
Family
ID=10668132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK299590A DK171298B1 (da) | 1989-12-19 | 1990-12-18 | Substituerede propan-1-ol-derivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdelde disse |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5118674A (OSRAM) |
| JP (1) | JPH04208256A (OSRAM) |
| KR (1) | KR910011759A (OSRAM) |
| AR (1) | AR246742A1 (OSRAM) |
| AT (1) | AT400333B (OSRAM) |
| AU (1) | AU630056B2 (OSRAM) |
| BE (1) | BE1004089A3 (OSRAM) |
| CA (1) | CA2032224C (OSRAM) |
| CH (1) | CH681624A5 (OSRAM) |
| DE (1) | DE4040685A1 (OSRAM) |
| DK (1) | DK171298B1 (OSRAM) |
| DZ (1) | DZ1471A1 (OSRAM) |
| ES (1) | ES2023607A6 (OSRAM) |
| FI (1) | FI906162L (OSRAM) |
| FR (2) | FR2656797B1 (OSRAM) |
| GB (2) | GB8928580D0 (OSRAM) |
| GR (1) | GR1000893B (OSRAM) |
| HK (1) | HK118093A (OSRAM) |
| IE (1) | IE65888B1 (OSRAM) |
| IN (1) | IN173969B (OSRAM) |
| IT (1) | IT1243412B (OSRAM) |
| LU (1) | LU87853A1 (OSRAM) |
| MA (1) | MA22013A1 (OSRAM) |
| MY (1) | MY104781A (OSRAM) |
| NL (1) | NL9002582A (OSRAM) |
| NO (1) | NO177146C (OSRAM) |
| NZ (1) | NZ236213A (OSRAM) |
| OA (1) | OA09475A (OSRAM) |
| PT (1) | PT96265B (OSRAM) |
| SE (1) | SE469383B (OSRAM) |
| TN (1) | TNSN90152A1 (OSRAM) |
| ZA (1) | ZA909663B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1132586C (zh) | 1993-09-09 | 2003-12-31 | 罗拉斯医疗公司 | 来自胆汁的免疫调节组合物、其制备方法及其用途 |
| US6551623B1 (en) | 1993-09-09 | 2003-04-22 | Lorus Therapeutics Inc. | Immunomodulating compositions from bile |
| NZ302638A (en) | 1995-03-16 | 2001-04-27 | Imutec Pharma Inc | Immunomodulating composition from bile for the treatment of immune system disorders |
| US20040101569A1 (en) * | 1996-05-16 | 2004-05-27 | Lorus Therapeutics Inc. | Immunomodulating compositions from bile |
| DE19711758C2 (de) * | 1997-03-21 | 2003-06-18 | Degussa | Verfahren zur Herstellung von 1,3-Dioxanverbindungen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2732263A1 (de) * | 1977-07-16 | 1979-02-01 | Schuler Gmbh L | Vorrichtung zum herstellen einer sicke am umfang eines hohlzylinders |
| DE2820893C2 (de) * | 1978-05-12 | 1986-02-20 | A. Nattermann & Cie GmbH, 5000 Köln | Strukturanaloga von natürlichen Phospholipiden und Verfahren zur Herstellung dieser Verbindungen |
| US4737518A (en) * | 1984-04-03 | 1988-04-12 | Takeda Chemical Industries, Ltd. | Lipid derivatives, their production and use |
| WO1989007099A1 (en) * | 1988-02-05 | 1989-08-10 | Schering Corporation | 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use |
| JP2534893B2 (ja) * | 1988-06-24 | 1996-09-18 | 日本ケミファ株式会社 | 新規なグリセリン誘導体およびその誘導体を含有する血小板凝集抑制剤 |
| DE3906952A1 (de) * | 1989-03-04 | 1990-09-06 | Boehringer Mannheim Gmbh | (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel |
| GR1000688B (el) * | 1989-12-22 | 1992-10-08 | Sod Conseils Rech Applic | Μεθοδος παρασκευης παραγωγων γλυκερινης. |
-
1989
- 1989-12-19 GB GB898928580A patent/GB8928580D0/en active Pending
-
1990
- 1990-11-16 IN IN1132DE1990 patent/IN173969B/en unknown
- 1990-11-16 GR GR900100812A patent/GR1000893B/el unknown
- 1990-11-26 NZ NZ236213A patent/NZ236213A/xx unknown
- 1990-11-26 CH CH3736/90A patent/CH681624A5/fr not_active IP Right Cessation
- 1990-11-27 US US07/618,700 patent/US5118674A/en not_active Expired - Fee Related
- 1990-11-27 NL NL9002582A patent/NL9002582A/nl not_active Application Discontinuation
- 1990-11-28 ES ES9003036A patent/ES2023607A6/es not_active Expired - Lifetime
- 1990-11-30 ZA ZA909663A patent/ZA909663B/xx unknown
- 1990-11-30 MY MYPI90002111A patent/MY104781A/en unknown
- 1990-12-05 AR AR90318536A patent/AR246742A1/es active
- 1990-12-06 LU LU87853A patent/LU87853A1/fr unknown
- 1990-12-10 MA MA22288A patent/MA22013A1/fr unknown
- 1990-12-12 NO NO905373A patent/NO177146C/no unknown
- 1990-12-13 CA CA002032224A patent/CA2032224C/en not_active Expired - Fee Related
- 1990-12-14 BE BE9001201A patent/BE1004089A3/fr not_active IP Right Cessation
- 1990-12-14 FI FI906162A patent/FI906162L/fi not_active IP Right Cessation
- 1990-12-16 DZ DZ900227A patent/DZ1471A1/fr active
- 1990-12-18 KR KR1019900020921A patent/KR910011759A/ko not_active Ceased
- 1990-12-18 SE SE9004039A patent/SE469383B/sv unknown
- 1990-12-18 AU AU68142/90A patent/AU630056B2/en not_active Ceased
- 1990-12-18 DK DK299590A patent/DK171298B1/da not_active IP Right Cessation
- 1990-12-18 GB GB9027421A patent/GB2239239B/en not_active Expired - Fee Related
- 1990-12-18 IE IE456790A patent/IE65888B1/en not_active IP Right Cessation
- 1990-12-19 IT IT02243890A patent/IT1243412B/it active IP Right Grant
- 1990-12-19 JP JP2417907A patent/JPH04208256A/ja active Pending
- 1990-12-19 TN TNTNSN90152A patent/TNSN90152A1/fr unknown
- 1990-12-19 OA OA59924A patent/OA09475A/xx unknown
- 1990-12-19 AT AT0259590A patent/AT400333B/de not_active IP Right Cessation
- 1990-12-19 FR FR909015900A patent/FR2656797B1/fr not_active Expired - Lifetime
- 1990-12-19 DE DE4040685A patent/DE4040685A1/de not_active Ceased
- 1990-12-19 PT PT96265A patent/PT96265B/pt not_active IP Right Cessation
- 1990-12-19 FR FR909015901A patent/FR2656307B1/fr not_active Expired - Lifetime
-
1993
- 1993-11-04 HK HK1180/93A patent/HK118093A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1428199A3 (ru) | Способ получени производных 2,2-иминобисэтанола или их кислотно-аддитивных солей,или их стереохимически изомерных форм (его варианты) | |
| US4876248A (en) | Anti-inflammatory products derived from methylene-diphosphonic acid, and process for their preparation | |
| FI58494C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten N-(1'-bentsyylipyrrolidin-2'-yylimetyyli) bentsamidien valmistamiseksi | |
| TW201735B (OSRAM) | ||
| SU1223843A3 (ru) | Способ получени 1-фенил-2-аминокарбонилиндольных соединений или их кислотно-аддитивных солей | |
| DK171021B1 (da) | Glycerolderivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdende disse | |
| JPS5951537B2 (ja) | 新規α−アミノオキシカルボン酸ヒドラジド誘導体の製造法 | |
| CA2032224C (en) | 3-(n-methyl-n-alkyl)-amino 2-methoxymethylene propan 1-ol derivatives, a preparation process of the same and therapeutical compositions containing them | |
| PT89082B (pt) | Processo para a preparacao de novos derivados n-(23-vinblastinoilicos) do acido 1-amino-metilfosfonico | |
| SU521839A3 (ru) | Способ получени производных бензофенона или их солей | |
| US2739152A (en) | Dialkylaminoalkyl esters of diarylisonicotinic acids | |
| NZ206293A (en) | (n-(2-chloroethyl)-n-nitrosoureido)-methyl phosphonic acid derivatives and pharmaceutical compositions | |
| US4605647A (en) | Oxaazaphosphorine compounds and pharmaceutical compositions | |
| CZ290863B6 (cs) | Deriváty fosfolipidů, způsob jejich výroby, léčiva a jejich pouľití a způsob výroby těchto léčiv | |
| US2731469A (en) | N-dialkylaminoalkyl derivatives of diarylisonicotinamides | |
| EP0174085A2 (en) | Bisarylamides of N,N'-di-[1-aminoalkyl-2]-alkylene diamines having a cardiovascular activity | |
| EP0465659A1 (en) | Piperazine compound, production thereof, and medicinal use thereof | |
| HU218655B (hu) | Daganatellenes hatású tioxantenonszármazékok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| SU722480A3 (ru) | Способ получени -аминоалкоксициклоалканов или их солей | |
| RU1814644C (ru) | Способ получени замещенных производных амина или их кислотно-аддитивных солей | |
| NO143221B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinderivater | |
| DK151630B (da) | Analogifremgangsmaade til fremstilling af n-phthalidyl-5-fluoruracilderivater | |
| HK74893A (en) | Substituted hydroxy-heterocyclyl-alkoxy phosphinyloxy trialkylaminium hydroxide inner salt oxides, processes for their preparation and their use as pharmaceuticals | |
| JPS6257191B2 (OSRAM) | ||
| JPS62178585A (ja) | １−〔３−（２−ヒドロキシ−３−アルキルアミノプロポキシ）−２−チエニル〕−３−フエニル−１−プロパノン及びそれらの酸付加塩並びにそれらの製造法及びそれらを含む薬学的組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |